Biostate AI, a Houston, TX-based artificial intelligence and RNA sequencing company, raised $12M in Series A funding.
The round was led by Accel with participation from Gaingels, Mana Ventures, InfoEdge Ventures, Matter Venture Partners, Vision Plus Capital, Catapult Ventures and angels included Dario Amodei (CEO, Anthropic), Mike Schnall-Levin (CTO, 10x Genomics), and Emily Leproust (CEO, Twist Bioscience).
The company intends to use the funds to expand operations and its R&D efforts.
Founded by David Zhang and Ashwin Gopinath, Biostate AI is a startup building generative AI that predicts the evolution of human disease and drug response based on RNA sequencing data. Its patented wetlab technologies, including BIRT, allow affordable and scalable collection of massive amounts of transcriptomic and genomic data.
With sites in Houston, TX, Palo Alto, CA, Bangalore, India, and Shanghai, China, the company partners with hospitals, academic researchers, and biotech/biopharma companies.
FinSMEs
21/05/2025